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In-vivo and ex-vivo functional assessmentThe assessment of the basic defect in individuals with
cystic fibrosis (CF) transforms the knowledge gained at the
bench to some spin-off for patients and CF physicians. In-
vivo and ex-vivo bioassays are an essential tool to make a
CF diagnosis, help to unravel the complex relationships
between the basic defect and the clinical manifestation of
disease, and are used as prime read-outs for causative
attempts to conquer CF by drugs or somatic gene transfer.
Section E of the ‘‘European Working Group on CFTR
Expression’’ focused on its objectives to provide documents
for the CF community to make a CF diagnosis based on
functional assays. The Gibson–Cooke pilocarpine iontopho-
resis sweat test has been and still is the gold standard to
diagnose CF. Numerous trials demonstrated its specificity,
sensitivity and reliability. Hence, the panel did not consider it
to be necessary to come up with any recommendations for
the sweat test. Instead, the methodology of the more recently
developed physiological assays Nasal Transepithelial Elec-
tric Potential Difference (NPD) and Intestinal Current Meas-
urements (ICM) has been extensively reviewed. The
contributors prepared a basic protocol for NPD measure-
ments [1] that is based on the experience of numerous North
American and European laboratories. Whereas a consensus
has been reached of how to perform NPD measurements, the
most appropriate protocol to execute ICM is still a subject of
debate. ICM assays are being performed in mini-Ussing
chambers under either short-circuit (Rotterdam protocol) or
open-circuit conditions (Freiburg protocol) with a slightly
different order of applied drugs. The ICM technique allows
the direct registration of CF-induced changes in electrogenic
transepithelial ion transport in a chloride (Cl) secretory
epithelium and on the basis of pharmacological criteria is
able to discriminate between CFTR-mediated Cl secretion
and secretion through alternative anion channels. In this
Special Issue, ICM is first presented in an editorial [2] that
describes the current state-of-the-art followed by the Rotter-
dam [3] and Freiburg [4] protocols for ex-vivo CF diagnosis
by ICM.
Single cell assays are the most recent technology to study
the basic defect in CF. X-ray microanalysis measures fluxes
of Cl and other ions in epithelial cells by the determination
of changes of elemental content of the cells in an electron
microscope [5]. A more widespread method to measure Cl
transport in cells are fluorescence quenching assays with
halide-sensitive fluorescent probes such as SPQ or MQAE1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.031[6]. The SPQ/MQAE assays yield reproducible and reliable
data for the assessment of halide flux in cultured epithelial
cell lines. However, the experts told me that the measure-
ments of halide efflux from human nasal or bronchial
brushings should be interpreted with caution and should
not be used for CF diagnosis.
In summary: the sweat test is still the major physiological
assay to diagnose CF. The applications of the more recent
physiological assays NPD and ICM predominantly include
 the differential diagnosis of atypical CF and CFTR-
opathies other than CF,
 the assessment of subjects with CF-like phenotypic
features with no or only one identifiable CFTR mutation,
 the assessment of subjects with CF-like phenotypic
features with normal or borderline sweat test values,
 the assessment of subjects harbouring CFTR sequence
variants of unresolved impact on disease,
 the assessment of residual Cl conductance,
 studies on the (therapeutic) modulation of the basic
defect, and
 CFTR genotype–phenotype studies.References
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